|
Pediatric Radiation Medical Countermeasures Working Group
|
Committee, Work group, Advisory group, or Task Force
|
ASPR, FDA
|
NIAID, NICHD
|
This group was established in an effort to harmonize efforts in the pediatric space and to push ahead pediatric radiation and multi-utility (Chem/Rad) products. The plan is to critically evaluate the status of pediatric drug development against radiation injury. Identify resources and cross-cutting efforts in this area to ensure a clear pathway is established to advance radiation products with a pediatric indication
|
|
Persistent Identifiers subgroup of the Subcommittee on Open Science of the National Science and Technology Council
|
Committee, Work group, Advisory group, or Task Force
|
ACL
|
NLM, OD, OD/DPCPSI/ODSS
|
The August 2022 OSTP Public Access Memo directed agencies to develop, among other things, an implementation plan for providing digital persistent identifiers for researchers, authors, affiliations, funding awards, research protocols, and research outputs. The PIDs working group shares information about existing services, issues, and needs toward supporting agency responses to provisions outlined in Section 4 of the Public Access Memo.
|
|
Physiological Effects of Natural or Contaminating Compounds in a Rodent's Microenvironment
|
Research Initiative
|
FDA
|
OD/OIR, NIEHS
|
Physiological Effects of Natural or Contaminating Compounds in a Rodent's Microenvironment
|
|
Pilot Biosurveillance Working Group - National Biodefense Strategy
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, ASPR
|
NIAID
|
This pilot working group was convened to develop objectives and work packages for biosurveillance topics in order to plan/implement these topics as indicated by the National Biodefense Strategy. A follow-on working group was to be convened.
|
|
Population Assessment of Tobacco and Health (PATH) Study
|
Health Survey
|
FDA
|
NIDA
|
The Population Assessment of Tobacco and Health (PATH) Study is the first large-scale National Institutes of Health (NIH)/ and the US Food and Drug Administration (FDA) collaboration since Congress granted FDA the authority to regulate tobacco products in the Family Smoking Prevention and Tobacco Control Act (FSPTCA) in 2009. The PATH Study is a national longitudinal cohort study that will follow an estimated 59,000 US household residents ages 12 years and older for at least three years. Objectives are to assess initiation and use patterns; to study trends in tobacco-product use cessation and relapse; to monitor behavioral and health impacts, including in risk perceptions and other tobacco-related attitudes; and to assess differences in tobacco-related attitudes, behaviors, and health outcomes among racial/ethnic, gender, and age subgroups. The PATH Study will also collect biospecimens from adults to analyze biomarkers of tobacco use and related health outcomes. By measuring and accurately reporting on the social, behavioral, and health effects associated with tobacco-product use in the United States, the PATH Study will provide an empirical evidence base to help inform FDA’s decisions about changes in tobacco products in meeting the objectives of the 2009 FSPTCA.
|
|
Post-Traumatic Stress Disorder (PTSD)/Trauma Brain Injury (TBI), Suicide Prevention National Research Action Plan (NRAP) Workgroup
|
Committee, Work group, Advisory group, or Task Force
|
OS
|
NIMH, NIAAA, NIDA, NINDS
|
A 2012 White House Executive Order, emphasizing support of Service Members, Veterans, and their families as a top priority, called for an urgent increase in the Departments of Health and Human Services (HHS), Defense (DoD), and Veterans Affairs (VA) research coordination to address the problems of Post-Traumatic Stress Disorders (PTSD), Trauma Brain Injury (TBI), and suicide. Section 5 of this Executive Order requested a National Research Action Plan (NRAP) to develop biomarkers, define the pathophysiology, and develop new treatments for PTSD. HHS charged the National Institute of Mental Health (NIMH) to lead this effort along with a parallel effort for TBI led by National Institute of Neurological Disorders and Stroke (NINDS), with both Institutes working closely with VA and DoD. The NRAP was published in 2013. Prior investments integrating the molecular, genomic, and brain circuitry changes that give rise to PTSD in the context of environmental factors provide the requisite foundation to respond to this White House request for biomarkers for risk prediction, as well as new targets for medications, and other therapies to treat PTSD. This investment has the potential to revolutionize care for individuals at high risk for PTSD and prevent the development of chronic, complex treatment-resistant PTSD. The agencies meet weekly and produce quarterly progress reports.
|
|
Postdoctoral Fellowship in Genomic Science and Health Equity
|
Training Initiative
|
FDA
|
NHGRI
|
The FDA, Office of Minority Health and Health Equity and the NHGRI jointly sponsor a postdoctoral fellowship program to provide training in genetic, genomic, and pharmacogenomic approaches to advance minority health and health equity. Working closely with mentors at both the FDA and NIH, this program helps fellows learn to bridge research, development and review processes, advance their knowledge of health disparities, and build awareness of regulatory sciences.
|
|
PRAMS Interagency Workgroup
|
Committee, Work group, Advisory group, or Task Force
|
CDC, NIH, CMS, HRSA
|
NICHD
|
Support team of PRAMS users as they build their internal capacity to link MCH data sets and inform their future programming.
|
|
Precision Oncology Interest Group (POIG)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCI, NIAID, NHLBI, NIDDK, NIAMS, NCATS, NINDS, NIBIB, NICHD, NIDCR, OD
|
The POIG, and its attendant listserv will aim to foster effective communication across the basic and clinical research oncology communities, to harness the translational powers of the NIH to advance precision therapy across cancers. The goals of the POIG are to discuss, plan, implement and execute the current CCR initiative to perform standardized genomic analyses (RNA-SEQ, exome-SEQ, methylation analysis) on a large cohort of NCI patients, with the goal of using these data to drive collaborative predictive and prognostic biomarker discovery and precision therapy strategies for improving patient outcomes, to discuss and implement best sample acquisition and management practices to learn the most from any precious patient material, to discuss and implement the best technologies and informatics to help us discover candidates for targeted therapies with the goal of maximizing favorable outcomes for oncology patients, and to rationally design clinical trials in oncology with a focus on precise therapies that have the potential to maximize benefit and minimize side effects.
|
|
Preclinical and Clinical Investigations of Severe Infection and Critical Illness - CDC Covid Response Team
|
Research Initiative
|
CDC
|
CC
|
Preclinical and Clinical Investigations of Severe Infection and Critical Illness - CDC Covid Response Team
|